9 March 2016 – The Board of Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, announces that on 8 March 2016, the Remuneration Committee approved the granting of share options to certain Directors to subscribe for ordinary shares of 1p each in the Company as follows:
|Director||No. of options granted||Percentage of issued share capital|
|Keith Neilson (CEO)||28,628||0.11|
|Craig Preston (CFO)||26,925||0.10|
The above options have been granted at an exercise price of 750p per share (being the closing market price on 8 March 2016). These options will be subject to performance criteria, such that they vest in three equal tranches over three years. One third of the share options will vest on or after 30 June 2016, one third on or after 30 June 2017 and the final third on or after 30 June 2018. The share options will not become exercisable until three years from the date of the grant.
For further information, please contact:
- +44 (0)20 7418 8900
- Dan Webster
- Richard Kauffer
- +44 (0)208 004 4218
- Caroline Forde
- Hilary Forde
Craneware is the leader in automated value cycle solutions that help US provider organisations discover, convert and optimise assets to achieve best clinical outcomes and financial performance. Founded in 1999, Craneware has headquarters in Edinburgh, Scotland with offices in Atlanta, Boston and Phoenix employing over 200 staff. Craneware’s market-driven, SaaS solutions normalise disparate data sets, bringing in up-to-date regulatory and financial compliance data to deliver value at the points where clinical and operational data transform into financial transactions, creating actionable insights that enable informed tactical and strategic decisions. To learn more, visit craneware.com.